1. Home
  2. UVE vs NTLA Comparison

UVE vs NTLA Comparison

Compare UVE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNIVERSAL INSURANCE HOLDINGS INC

UVE

UNIVERSAL INSURANCE HOLDINGS INC

HOLD

Current Price

$29.65

Market Cap

925.9M

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.06

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVE
NTLA
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
925.9M
986.9M
IPO Year
1992
2016

Fundamental Metrics

Financial Performance
Metric
UVE
NTLA
Price
$29.65
$12.06
Analyst Decision
Buy
Buy
Analyst Count
1
22
Target Price
$40.00
$19.83
AVG Volume (30 Days)
210.9K
4.2M
Earning Date
02-24-2026
02-26-2026
Dividend Yield
2.58%
N/A
EPS Growth
70.32
N/A
EPS
4.23
N/A
Revenue
$1,580,798,000.00
$57,528,000.00
Revenue This Year
$1.87
$1.96
Revenue Next Year
N/A
N/A
P/E Ratio
$7.05
N/A
Revenue Growth
4.61
33.52
52 Week Low
$18.72
$5.90
52 Week High
$35.84
$28.25

Technical Indicators

Market Signals
Indicator
UVE
NTLA
Relative Strength Index (RSI) 37.09 70.92
Support Level $29.11 $10.13
Resistance Level $31.25 $9.62
Average True Range (ATR) 1.13 0.61
MACD -0.39 0.40
Stochastic Oscillator 8.31 93.97

Price Performance

Historical Comparison
UVE
NTLA

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: